135 related articles for article (PubMed ID: 38771836)
1. Prevalence and risk factors of cytomegalovirus reactivation in critically Ill patients with COVID-19 pneumonia.
Tassaneeyasin T; Sungkanuparph S; Srichatrapimuk S; Charoensri A; Thammavaranucupt K; Jayanama K; Kirdlarp S
PLoS One; 2024; 19(5):e0303995. PubMed ID: 38771836
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus reactivation in critically ill immunocompetent patients.
Limaye AP; Kirby KA; Rubenfeld GD; Leisenring WM; Bulger EM; Neff MJ; Gibran NS; Huang ML; Santo Hayes TK; Corey L; Boeckh M
JAMA; 2008 Jul; 300(4):413-22. PubMed ID: 18647984
[TBL] [Abstract][Full Text] [Related]
3. Association between Pulmonary Aspergillosis and
Caciagli V; Coloretti I; Talamonti M; Farinelli C; Gatto I; Biagioni E; Sarti M; Franceschini E; Meschiari M; Mussini C; Tonelli R; Clini E; Girardis M; Busani S; Modena Covid-Working Group
Viruses; 2023 Nov; 15(11):. PubMed ID: 38005936
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus reactivation in a general, nonimmunosuppressed intensive care unit population: incidence, risk factors, associations with organ dysfunction, and inflammatory biomarkers.
Frantzeskaki FG; Karampi ES; Kottaridi C; Alepaki M; Routsi C; Tzanela M; Vassiliadi DA; Douka E; Tsaousi S; Gennimata V; Ilias I; Nikitas N; Armaganidis A; Karakitsos P; Papaevangelou V; Dimopoulou I
J Crit Care; 2015 Apr; 30(2):276-81. PubMed ID: 25457114
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus blood reactivation in COVID-19 critically ill patients: risk factors and impact on mortality.
Gatto I; Biagioni E; Coloretti I; Farinelli C; Avoni C; Caciagli V; Busani S; Sarti M; Pecorari M; Gennari W; Guaraldi G; Franceschini E; Meschiari M; Mussini C; Tonelli R; Clini E; Cossarizza A; Girardis M;
Intensive Care Med; 2022 Jun; 48(6):706-713. PubMed ID: 35583676
[TBL] [Abstract][Full Text] [Related]
6. Reactivation of EBV and CMV in Severe COVID-19-Epiphenomena or Trigger of Hyperinflammation in Need of Treatment? A Large Case Series of Critically ill Patients.
Naendrup JH; Garcia Borrega J; Eichenauer DA; Shimabukuro-Vornhagen A; Kochanek M; Böll B
J Intensive Care Med; 2022 Sep; 37(9):1152-1158. PubMed ID: 34791940
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus reactivation and associated outcome of critically ill patients with severe sepsis.
Heininger A; Haeberle H; Fischer I; Beck R; Riessen R; Rohde F; Meisner C; Jahn G; Koenigsrainer A; Unertl K; Hamprecht K
Crit Care; 2011; 15(2):R77. PubMed ID: 21362193
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Antiviral Therapy for Prevention of Cytomegalovirus Reactivation in Immunocompetent Critically Ill Patients: A Randomized Clinical Trial.
Cowley NJ; Owen A; Shiels SC; Millar J; Woolley R; Ives N; Osman H; Moss P; Bion JF
JAMA Intern Med; 2017 Jun; 177(6):774-783. PubMed ID: 28437539
[TBL] [Abstract][Full Text] [Related]
9. Reactivation of Latent Cytomegalovirus Infection after Major Surgery: Risk Factors and Outcomes.
Gardiner BJ; Herrick KW; Bailey RC; Chow JK; Snydman DR
Surg Infect (Larchmt); 2019 Jul; 20(5):416-423. PubMed ID: 30912706
[No Abstract] [Full Text] [Related]
10. Interferon-γ production by CMV-specific CD8+ T lymphocytes provides protection against cytomegalovirus reactivation in critically ill patients.
Castón JJ; Cantisán S; González-Gasca F; Páez-Vega A; Abdel-Hadi H; Illescas S; Alonso G; Torre-Cisneros J
Intensive Care Med; 2016 Jan; 42(1):46-53. PubMed ID: 26537489
[TBL] [Abstract][Full Text] [Related]
11. Effect of Ganciclovir on IL-6 Levels Among Cytomegalovirus-Seropositive Adults With Critical Illness: A Randomized Clinical Trial.
Limaye AP; Stapleton RD; Peng L; Gunn SR; Kimball LE; Hyzy R; Exline MC; Files DC; Morris PE; Frankel SK; Mikkelsen ME; Hite D; Enfield KB; Steingrub J; O'Brien J; Parsons PE; Cuschieri J; Wunderink RG; Hotchkin DL; Chen YQ; Rubenfeld GD; Boeckh M
JAMA; 2017 Aug; 318(8):731-740. PubMed ID: 28829877
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation.
Massoud R; Assi R; Fares E; Haffar B; Charafeddine M; Kreidieh N; Mahfouz R; Kanj SS; El Zakhem A; Kharfan-Dabaja M; Bazarbachi A; El Cheikh J
J Clin Virol; 2017 Oct; 95():36-41. PubMed ID: 28843110
[TBL] [Abstract][Full Text] [Related]
13. Impact of antiviral treatment on long-term prognosis in non-immunocompromised patients with CMV reactivation.
Park GE; Ki HK; Ko JH
BMC Infect Dis; 2021 May; 21(1):414. PubMed ID: 33947335
[TBL] [Abstract][Full Text] [Related]
14. Looking for biological factors to predict the risk of active cytomegalovirus infection in non-immunosuppressed critically ill patients.
Bravo D; Clari MA; Aguilar G; Belda J; Giménez E; Carbonell JA; Henao L; Navarro D
J Med Virol; 2014 May; 86(5):827-33. PubMed ID: 24431153
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus reactivation in patients diagnosed with severe COVID-19: A point prevalence study in a general hospital.
Pérez-Granda MJ; Catalán P; Muñoz P; Aldámiz T; Barrios JC; Ramírez C; García-Martínez R; Villalba MV; Puente L; Bouza E
Rev Esp Quimioter; 2023 Feb; 36(1):45-51. PubMed ID: 36408974
[TBL] [Abstract][Full Text] [Related]
16. Optimal pre-emptive cytomegalovirus therapy threshold in a patient population with high prevalence of seropositive status.
Damlaj M; Khalid F; Alahmari B; Alaskar A; Ghazi S; Johani S; AlSaedy A; Bosaeed M; Alhejazi A; Al-Zahrani M
Curr Res Transl Med; 2020 Aug; 68(3):131-137. PubMed ID: 32620466
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus Reactivation Is Associated with Increased Risk of Late-Onset Invasive Fungal Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Study in the Current Era of Viral Load Monitoring.
Yong MK; Ananda-Rajah M; Cameron PU; Morrissey CO; Spencer A; Ritchie D; Cheng AC; Lewin SR; Slavin M
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1961-1967. PubMed ID: 28797778
[TBL] [Abstract][Full Text] [Related]
18. Burden of cytomegalovirus reactivation post kidney transplant with antithymocyte globulin use in Thailand: A retrospective cohort study.
Chitasombat MN; Watcharananan SP
F1000Res; 2018; 7():1568. PubMed ID: 30473779
[No Abstract] [Full Text] [Related]
19. CMV in critically ill patients: pathogen or bystander?
Limaye AP; Boeckh M
Rev Med Virol; 2010 Nov; 20(6):372-9. PubMed ID: 20931610
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus reactivation in immunocompetent mechanical ventilation patients: a prospective observational study.
Zhang Z; Liu X; Sang L; Chen S; Wu Z; Zhang J; Sun Y; Huang Y; Xu Y; He W; Li Y; Liu X
BMC Infect Dis; 2021 Sep; 21(1):1026. PubMed ID: 34592936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
